




Ocera Therapeutics, Inc.
Investor Relations Department
5001 S. Miami Boulevard,
Suite 300
Durham, NC 27703
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: OCRX

| | |
|---------------|---|
| Last Trade: | 1.25 |
| Trade Time: | 3:59 PM ET Jul 21, 2017 |
| Change: | -0.01  (-0.794%) |
| Day Range | 1.22 - 1.27 |
| 52-Week Range | 0.52 - 3.15 |
| Volume | 150,207 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.


Company Profile

[Ocera Therapeutics](#)

(NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 1, 2017

[Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis](#)

May 26, 2017

[Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2](#)

May 9, 2017

[Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update](#)

May 3, 2017

[Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017](#)

Apr 12, 2017

[Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease \(NAFLD\)](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 14, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)